This is where all download will be listed, utilizing the Page Add plugin.
File Name | S22-Policy-Stoa-30-AFF-MCED.docx |
File Size | 297.13 KB |
Date added | December 20, 2021 |
Category | Policy (Stoa) |
Author | Vance Trefethen |
Resolved: The United States federal government substantially reform the use of Artificial Intelligence technology
Case Summary: Plan passes the Medicare Multi-Cancer Early Detection Screening Coverage Act, a bill pending in Congress but not yet enacted. It amends Title XVIII of the Social Security Act to allow Medicare to cover any MCED tests that are approved by the FDA. MCED is an AI-driven revolutionary technique for early detection of cancer. It can detect cells deposited in the blood that are markers for dozens of types of cancer, many of which have zero methods of early screening today. A simple blood test can catch cancer much earlier and allow treatment before it gets too bad to treat. The “Multi” part is important too: One test catches multiple different possible cancer types, something no test today can do.
Medicare pays for 1/3 of all cancer treatment in the US every year. But because MCED is so new, and has not received final approval by the FDA (it will happen any day now), Medicare won’t pay for it. It takes specific legislation from Congress to tell Medicare to cover it. The MCED Screening Coverage Act directs Medicare to pay for any MCED approved by the FDA. Our backup evidence specifically advocates passing this bill BEFORE the FDA finalizes the approval, which should stop any whining by Negatives that it’s not ready yet. And some MCED tests have already started rolling out on a limited basis, even without FDA approval – a pretty good indicator that they’re coming soon.
This plan and its backup evidence has exact numbers and quantifications for every statistic a Negative could consider complaining about.